Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2010-07, Vol.363 (3), p.257-265
Hauptverfasser: Severe, Patrice, Jean Juste, Marc Antoine, Ambroise, Alex, Eliacin, Ludger, Marchand, Claudel, Apollon, Sandra, Edwards, Alison, Bang, Heejung, Nicotera, Janet, Godfrey, Catherine, Gulick, Roy M, Johnson, Warren D, Pape, Jean William, Fitzgerald, Daniel W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 265
container_issue 3
container_start_page 257
container_title The New England journal of medicine
container_volume 363
creator Severe, Patrice
Jean Juste, Marc Antoine
Ambroise, Alex
Eliacin, Ludger
Marchand, Claudel
Apollon, Sandra
Edwards, Alison
Bang, Heejung
Nicotera, Janet
Godfrey, Catherine
Gulick, Roy M
Johnson, Warren D
Pape, Jean William
Fitzgerald, Daniel W
description The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis. Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased. The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .
doi_str_mv 10.1056/NEJMoa0910370
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3676927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734001237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</originalsourceid><addsrcrecordid>eNp10c9vFCEUB3BiNHatHr2aiYnxNMqvgeVi0jSru6bVg9UrecOAZTMDKzCb7H8vTdfWmkgCHPjk8YWH0EuC3xHcifdfVp8vI2BFMJP4EVqQjrGWcyweowXGdNlyqdgJepbzFtdBuHqKTigWXFJMFuhyBWk8NHub8pybbwXCAGlozkLxyZYU9z7B2Fxd2wS7Q-NiatabH-0mOGuKrW6Yx5IbH5o1-OKfoycOxmxfHPdT9P3j6up83V58_bQ5P7toTcdUqWtHQVJuFHWC1dm7nisJjMOSYcDSKCdk3y0BCHdEdlYNQCixQAhlvWWn6MNt3d3cT3YwNpQaU--SnyAddASvH54Ef61_xr1mQgpFZS3w9lggxV-zzUVPPhs7jhBsnLOWjNe_ouxGvv5HbuOcQn2dFoQuMe0Erai9RSbFnJN1d1EI1jdt0g_aVP2rv_Pf6T99qeDNEUA2MLoEwfh876hSiip-76Yp62C3038u_A2T7aWn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>612802562</pqid></control><display><type>article</type><title>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Severe, Patrice ; Jean Juste, Marc Antoine ; Ambroise, Alex ; Eliacin, Ludger ; Marchand, Claudel ; Apollon, Sandra ; Edwards, Alison ; Bang, Heejung ; Nicotera, Janet ; Godfrey, Catherine ; Gulick, Roy M ; Johnson, Warren D ; Pape, Jean William ; Fitzgerald, Daniel W</creator><creatorcontrib>Severe, Patrice ; Jean Juste, Marc Antoine ; Ambroise, Alex ; Eliacin, Ludger ; Marchand, Claudel ; Apollon, Sandra ; Edwards, Alison ; Bang, Heejung ; Nicotera, Janet ; Godfrey, Catherine ; Gulick, Roy M ; Johnson, Warren D ; Pape, Jean William ; Fitzgerald, Daniel W</creatorcontrib><description>The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis. Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased. The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa0910370</identifier><identifier>PMID: 20647201</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; AIDS-Related Opportunistic Infections - drug therapy ; Anti-Retroviral Agents - administration &amp; dosage ; Anti-Retroviral Agents - adverse effects ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antitubercular Agents - therapeutic use ; Antiviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Drug Administration Schedule ; Drug therapy ; Female ; Follow-Up Studies ; General aspects ; Haiti ; HIV ; HIV Infections - drug therapy ; HIV Infections - mortality ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Kaplan-Meier Estimate ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Tropical diseases ; Tuberculosis, Pulmonary - drug therapy ; Tuberculosis, Pulmonary - epidemiology ; Tuberculosis, Pulmonary - prevention &amp; control ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>The New England journal of medicine, 2010-07, Vol.363 (3), p.257-265</ispartof><rights>Copyright © 2010 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><rights>2010 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</citedby><cites>FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa0910370$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa0910370$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22999294$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20647201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Severe, Patrice</creatorcontrib><creatorcontrib>Jean Juste, Marc Antoine</creatorcontrib><creatorcontrib>Ambroise, Alex</creatorcontrib><creatorcontrib>Eliacin, Ludger</creatorcontrib><creatorcontrib>Marchand, Claudel</creatorcontrib><creatorcontrib>Apollon, Sandra</creatorcontrib><creatorcontrib>Edwards, Alison</creatorcontrib><creatorcontrib>Bang, Heejung</creatorcontrib><creatorcontrib>Nicotera, Janet</creatorcontrib><creatorcontrib>Godfrey, Catherine</creatorcontrib><creatorcontrib>Gulick, Roy M</creatorcontrib><creatorcontrib>Johnson, Warren D</creatorcontrib><creatorcontrib>Pape, Jean William</creatorcontrib><creatorcontrib>Fitzgerald, Daniel W</creatorcontrib><title>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis. Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased. The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>Anti-Retroviral Agents - administration &amp; dosage</subject><subject>Anti-Retroviral Agents - adverse effects</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Haiti</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Tropical diseases</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><subject>Tuberculosis, Pulmonary - epidemiology</subject><subject>Tuberculosis, Pulmonary - prevention &amp; control</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10c9vFCEUB3BiNHatHr2aiYnxNMqvgeVi0jSru6bVg9UrecOAZTMDKzCb7H8vTdfWmkgCHPjk8YWH0EuC3xHcifdfVp8vI2BFMJP4EVqQjrGWcyweowXGdNlyqdgJepbzFtdBuHqKTigWXFJMFuhyBWk8NHub8pybbwXCAGlozkLxyZYU9z7B2Fxd2wS7Q-NiatabH-0mOGuKrW6Yx5IbH5o1-OKfoycOxmxfHPdT9P3j6up83V58_bQ5P7toTcdUqWtHQVJuFHWC1dm7nisJjMOSYcDSKCdk3y0BCHdEdlYNQCixQAhlvWWn6MNt3d3cT3YwNpQaU--SnyAddASvH54Ef61_xr1mQgpFZS3w9lggxV-zzUVPPhs7jhBsnLOWjNe_ouxGvv5HbuOcQn2dFoQuMe0Erai9RSbFnJN1d1EI1jdt0g_aVP2rv_Pf6T99qeDNEUA2MLoEwfh876hSiip-76Yp62C3038u_A2T7aWn</recordid><startdate>20100715</startdate><enddate>20100715</enddate><creator>Severe, Patrice</creator><creator>Jean Juste, Marc Antoine</creator><creator>Ambroise, Alex</creator><creator>Eliacin, Ludger</creator><creator>Marchand, Claudel</creator><creator>Apollon, Sandra</creator><creator>Edwards, Alison</creator><creator>Bang, Heejung</creator><creator>Nicotera, Janet</creator><creator>Godfrey, Catherine</creator><creator>Gulick, Roy M</creator><creator>Johnson, Warren D</creator><creator>Pape, Jean William</creator><creator>Fitzgerald, Daniel W</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100715</creationdate><title>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</title><author>Severe, Patrice ; Jean Juste, Marc Antoine ; Ambroise, Alex ; Eliacin, Ludger ; Marchand, Claudel ; Apollon, Sandra ; Edwards, Alison ; Bang, Heejung ; Nicotera, Janet ; Godfrey, Catherine ; Gulick, Roy M ; Johnson, Warren D ; Pape, Jean William ; Fitzgerald, Daniel W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-c552a724c92f632f6bfb497a34a830a07c9f67b58aa14f175e9da121ea1123be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>Anti-Retroviral Agents - administration &amp; dosage</topic><topic>Anti-Retroviral Agents - adverse effects</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Haiti</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Tropical diseases</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><topic>Tuberculosis, Pulmonary - epidemiology</topic><topic>Tuberculosis, Pulmonary - prevention &amp; control</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Severe, Patrice</creatorcontrib><creatorcontrib>Jean Juste, Marc Antoine</creatorcontrib><creatorcontrib>Ambroise, Alex</creatorcontrib><creatorcontrib>Eliacin, Ludger</creatorcontrib><creatorcontrib>Marchand, Claudel</creatorcontrib><creatorcontrib>Apollon, Sandra</creatorcontrib><creatorcontrib>Edwards, Alison</creatorcontrib><creatorcontrib>Bang, Heejung</creatorcontrib><creatorcontrib>Nicotera, Janet</creatorcontrib><creatorcontrib>Godfrey, Catherine</creatorcontrib><creatorcontrib>Gulick, Roy M</creatorcontrib><creatorcontrib>Johnson, Warren D</creatorcontrib><creatorcontrib>Pape, Jean William</creatorcontrib><creatorcontrib>Fitzgerald, Daniel W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Severe, Patrice</au><au>Jean Juste, Marc Antoine</au><au>Ambroise, Alex</au><au>Eliacin, Ludger</au><au>Marchand, Claudel</au><au>Apollon, Sandra</au><au>Edwards, Alison</au><au>Bang, Heejung</au><au>Nicotera, Janet</au><au>Godfrey, Catherine</au><au>Gulick, Roy M</au><au>Johnson, Warren D</au><au>Pape, Jean William</au><au>Fitzgerald, Daniel W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2010-07-15</date><risdate>2010</risdate><volume>363</volume><issue>3</issue><spage>257</spage><epage>265</epage><pages>257-265</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>The optimal time to initiate antiretroviral therapy in HIV-infected adults, especially in resource-poor areas, is debated. In this study of HIV-infected adults in Haiti, the investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rate of death was decreased, as was the rate of incident tuberculosis. Investigators found that when antiretroviral therapy was initiated when the CD4 count was greater than 200 and less than 350 per cubic millimeter, as compared with waiting until the CD4 count fell to 200 per cubic millimeter or less, the rates of death and of incident tuberculosis were decreased. The optimal time to initiate antiretroviral therapy in adults who are infected with human immunodeficiency virus (HIV) remains uncertain. There have been no randomized trials to determine the optimal time to start antiretroviral therapy in adults who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter. Furthermore, there are few data on the optimal time to start antiretroviral therapy in persons who live in locations with limited resources, where high rates of tuberculosis, malnutrition, and coinfection with tropical diseases may alter the natural history of HIV disease and the optimal time to initiate . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>20647201</pmid><doi>10.1056/NEJMoa0910370</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2010-07, Vol.363 (3), p.257-265
issn 0028-4793
1533-4406
1533-4406
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3676927
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine
subjects Acquired immune deficiency syndrome
Adult
AIDS
AIDS-Related Opportunistic Infections - drug therapy
Anti-Retroviral Agents - administration & dosage
Anti-Retroviral Agents - adverse effects
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
Antitubercular Agents - therapeutic use
Antiviral agents
Biological and medical sciences
CD4 Lymphocyte Count
Drug Administration Schedule
Drug therapy
Female
Follow-Up Studies
General aspects
Haiti
HIV
HIV Infections - drug therapy
HIV Infections - mortality
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Kaplan-Meier Estimate
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Tropical diseases
Tuberculosis, Pulmonary - drug therapy
Tuberculosis, Pulmonary - epidemiology
Tuberculosis, Pulmonary - prevention & control
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
title Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A50%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20versus%20Standard%20Antiretroviral%20Therapy%20for%20HIV-Infected%20Adults%20in%20Haiti&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Severe,%20Patrice&rft.date=2010-07-15&rft.volume=363&rft.issue=3&rft.spage=257&rft.epage=265&rft.pages=257-265&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa0910370&rft_dat=%3Cproquest_pubme%3E734001237%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=612802562&rft_id=info:pmid/20647201&rfr_iscdi=true